ACTRN12620000447954撤回未知
se of therapeutic drug monitoring (TDM) to optimise oral/enteral hydroxychloroquine dosing in critically ill patients with COVID-19
适应症
试验速览
- 阶段
- 未知
- 状态
- 撤回
- 入组人数
- 150
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Non-randomised trial
- 主要目的
- Treatment
- 盲法
- Open (masking not used)
入排标准
- 年龄范围
- 18 Years 至 o limit（—）
- 性别
- All
入选标准
- •Patients admitted to ICU at the Royal Brisbane & Women's Hospital with suspected or proven severe COVID-19 infection, prescribed hydroxychloroquine as part of their routine management.
排除标准
- •Individuals aged <18 years old.
研究者
相似试验
招募中
3 期
Assessment of Memantine Drug Levels in Blood Among Indian Patients with Brain Metastases Treated with Radiation TherapyCTRI/2024/04/066217Amrita School of Pharmacy
已完成
3 期
Therapeutic drug monitoring-based dose optimisation of piperacillin in patients with severe sepsis or septic shock to investigate effects on organ functions and survival: a prospective, multicenter, randomized controlled trialR65.1R57.2Systemic Inflammatory Response Syndrome of infectious origin with organ failureSeptic shockDRKS00011159Friedrich-Schiller-Universität Jena254
招募中
不适用
Influence of therapeutic drug monitoring (TDM) on the tolerability and efficacy of 5-FU-containing chemotherapy in patients with colorectal carcinoma in the colorectal center at St.-Franziskus-Hospital Münster: a prospective, monocentric observational study.C18Malignant neoplasm of colonDRKS00026926St. Franziskus-Hospital GmbH50
进行中（未招募）
不适用
Effectiveness of theraPeutic drug mOnitoring (TDM) on mucosal and transmural healing in pediatric patients with moderate to severe luminal CroHn’s disease newly receiving Remsima(infliximab): EPOCH studyDiseases of the digestive systemKCT0005190Samsung Medical Center116
进行中（未招募）
1 期
Measurement of the blood concentration of the antibiotic piperacillin and individual drug dosage in patients with febrile neutropenia after chemotherapyPatients with febrile neutropenia after myelo-suppressive chemotherapy treated with piperacillin/tazobactamEUCTR2016-002388-33-DEFriedrich-Schiller-University Jena208